Method of preventing and treating inflammatory diseases and disorders with abscisic acid
The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
1. A method of treating respiratory inflammation in a mammal, the method comprising administering to the mammal a composition containing one or more compounds selected from: abscisic acid (ABA) in its free acid form, esters thereof, pharmaceutically suitable salts thereof, metabolites thereof, structurally related compounds thereof, and analogs thereof, in amounts that are sufficient to decrease mucosal and submucosal inflammatory cell infiltration, perivascular cuffing, terminal airway infiltration, or epithelial necrosis in the lung, wherein the inflammation is caused by an infection of a respiratory pathogen selected from the group consisting of influenza virus rhinovirus respiratory syncytial virus, parainfluenza, Staphylococcus aureus, Streptococcus pneumoniae, Francisella tularensis, Mycobacterium tuberculosis and Bacillus anthracis.
2. The method of claim 1 , wherein the composition further contains a carrier.
3. The method of claim 2 , wherein the carrier is a nutritional supplement, functional food, or dietary aid.
4. The method of claim 1 , wherein the one or more compounds is abscisic acid in its free acid form.
5. The method of claim 4 , wherein the abscisic acid in its free acid form is chemically synthesized.
6. The method of claim 4 , wherein the amount of the composition is also sufficient to decrease accumulation of tipDC in the lungs.